

WINSTON & STRAWN LLP

1400 L STREET, N.W., WASHINGTON, DC 20005-3502
202-371-570035 W. Wacker Drive
Chicago, IL 60601-3900
312-556-5000800 Penn Avenue
New York, NY 10119-4199
212-694-6700300 N. LaSalle, 303 South Ohio Ave
Los Angeles, CA 90012-1147
213-615-1700101 California Street
San Francisco, CA 94111-4200
415-391-1000435 Rte Du Pont
1800 Centre, Wilmington
DE 19801-0900
302-317-707081 Avenue Victor Hugo
75116 Paris, France
33-1-5364-020225 Old Derby Road
3 Old Derby Road
London, England EC4A 3DF
44-207-7429-0000

Fax Number: 202-371-5950

FROM: Elizabeth Anderson

APPLN. No.: 10/669,476

DATE: March 23, 2005

OUR REF.: 85189-498

Please Deliver as Soon as Possible To:

RECIPIENT	COMPANY	FAX No.	PHONE No.
Office of Initial Patent Examination, Filing Receipt Corrections	U.S. Patent and Trademark Office	703-746-9195	703-308-1202

Total number of pages including this page: 8

COMMENTS

SECOND REQUEST

In re Application of: Abraham SHAHAR et al.

Confirmation No.: 4834

Application No.: 10/669,476

Art Unit: 1651

Filed: September 23, 2003

Examiner:

For: CROSS-LINKED HYALURONIC
ACID-LAMININ GELS AND USE
THEREOF IN CELL CULTURE
AND MEDICAL IMPLANTS

Attorney Docket No.: 85189-498

Please see attached Request for Correction of Filing Receipt.

IF YOU DO NOT RECEIVE ALL PAGES, PLEASE CALL 202-216-8602 AS SOON AS POSSIBLE. THANK YOU.

The information contained in this facsimile message is attorney privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited.

If you have received this communication in error, please immediately notify us by telephone, and return the original message to us at the above address via the U.S. Postal Service. Thank you.

DC:394941.2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Abraham SHAHAR et al.	Confirmation No.: 4834
Application No.: 10/669,476	Group Art Unit: 1651
Filing Date: September 23, 2003	Examiner:
For: CROSS-LINKED HYALURONIC ACID- LAMININ GELS AND USE THEREOF IN CELL CULTURE AND MEDICAL IMPLANTS	Attorney Docket No.: 85189-498

REQUEST FOR CORRECTION OF FILING RECEIPT

Office of Initial Patent Examination
Customer Service Center
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to applicants Request for Correction of Filing Receipt filed June 24, 2004, applicants have received a Response indicating that the Office could not comply with the request to add application no. 60/382,341 as domestic continuity because "a claim for priority cannot be made based on an application filed after the application making the claim."

As stated on page 1 of the specification at "Cross-Reference to Related Applications," the present application is a continuation of 10/445,394 filed May 23, 2003, which is a continuation-in-part of 10/437,663 filed May 13, 2003, which is a continuation of PCT/IL01/01050 filed November 13, 2001, which claims the benefit of 60/248,447 filed November 14, 2000, and also claims the benefit of 60/382,341 filed May 23, 2002. The domestic priority data is also identified on applicants' Declaration filed September 23, 2003. Therefore, it is proper that application no. 60/382,341 filed May 23, 2002 be included as a domestic priority application.

Thus, applicants respectfully request that the Filing Receipt be amended as follows:
At Domestic Priority data as claimed by Applicant, please add: -- and claims the benefit of 60/382,341 05/23/2002 --.

DC:394869.1


- 1 -

A copy of the Filing Receipt with the requested change noted thereon is enclosed,
along with a copy of page 1 of the specification and the Declaration in support thereof.

No fee is believed to be due for this submission. Should any fees be required,
however, please charge such fees to Winston & Strawn LLP Deposit Account No. 50-1814.

Respectfully submitted,

Jan 7, 2005
Date


E. Bradley Gould (Reg. No. 41,792)
For: Allan A. Fanucci (Reg. No. 30,256)

WINSTON & STRAWN LLP
Customer No. 28765

202-371-5771



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22311-1450
Telephone: (571) 272-1100

APPL NO.	FILING OR 371 (a) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/689,476	08/23/2003	1851	552	85189-488	13	35	4

28765
WINSTON & STRAWN
PATENT DEPARTMENT
1400 L STREET, N.W.
WASHINGTON, DC 20005-3502

CONFIRMATION NO. 4834

CORRECTED FILING RECEIPT



0000000013393168

Date Mailed: 07/30/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Abraham Shahar, Rehovot, ISRAEL;
Zvi Nevo, Herzlia, ISRAEL;
Shimon Rochkind, Ramat Aviv Gimel, ISRAEL;

Domestic Priority data as claimed by applicant

This application is a CON of 10/445,394 05/23/2003
which is a CIP of 10/437,883 05/13/2003 ABN
which is a CON of PCT/IL01/01050 11/13/2001
which claims benefit of 80/248,447 11/14/2000
and claims the benefit of 60/382,341 05/23/2002

Foreign Applications

If Required, Foreign Filing License Granted: 12/15/2003

Projected Publication Date: 08/17/2004

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**CROSS-LINKED HYALURONIC ACID-LAMININ GELS AND
USE THEREOF IN CELL CULTURE AND MEDICAL IMPLANTS**

1. CROSS-REFERENCE TO RELATED APPLICATION

5 This application is a continuation of US application no. 10/445,394 filed May 23, 2003, an application which is a continuation-in-part of US application no. 10/437,663 filed May 13, 2003, an application which is a continuation of International Application PCT/IL01/01050 filed November 13, 2001, which application claims the benefit of US provisional application 60/248,447 filed November 14, 2000. This application also claims
10 the benefit of US provisional application 60/382,341 filed May 23, 2002. The entire content of each application is expressly incorporated herein by reference thereto.

2. FIELD OF THE INVENTION

15 The present invention concerns universal biocompatible matrices comprising cross-linked hyaluronic acid-laminin gels, processes of making these gels and uses thereof for clinical applications including as implants for guided tissue regeneration, for tissue engineering and for coating of medical devices, as well as in biotechnology.

3. BACKGROUND OF THE INVENTION

20 The ability to induce and guide tissue regeneration is an unmet medical need, particularly in systems such as the central nervous system and the cardiovascular system where loss of function results in severe debilitation or death.

Neuronal cell death as a result of injury, ischemia or degeneration within the central nervous system (CNS) is generally considered irreversible. Nerve regeneration is largely
25 considered an unattainable goal within the CNS, due to the inability of these cell types to multiply after maturation, which occurs early in life. Axonal injury within the central nervous system is also generally thought to be irreversible when it involves severance of the axons. Various reports of success in nerve regeneration in animal models have not yet led to any satisfactory therapeutic approach to this problem, though it is envisaged that
30 implants or transplants containing viable neurons or their progenitors, possibly derived from human embryonic stem cells, may one day provide an option for attaining CNS regeneration.

NY:781255.1

23 SEP 2003 16:43:56

WEBB & ASSOCIATES 972 8 9470860
NO. 895 P. 3NO. 051 P. 5
NO. 895 P. 3

WINSTON & STRAWN DOCKET NO.: 88189-498

DECLARATION FOR NON-PROVISIONAL PATENT APPLICATION

As a below-named inventor, I hereby declare that

My residence, past office address and citizenship are as stated below at 201 et seq. beneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names are listed at 201 et seq. below, of the subject matter which is claimed and for which a patent is sought in the invention entitled

CROSS-LINKED HYALURONIC ACID-LAMININ GELS AND USE THEREOF IN CELL CULTURE AND MEDICAL IMPLANTS

and for which a patent application:

- ☒ is attached hereto and includes amendment(s) filed on _____ (if applicable)
☐ was filed in the United States on _____ as Application No. _____ (if applicable)
☐ was filed as PCT International Application No. _____ on _____ (if applicable)
☐ was filed as PCT International Application No. _____ on _____ (if applicable) and was amended under PCT Article 19 on _____ (if applicable)

I hereby state that I have reviewed and understood the contents of the above identified application, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED PRIOR TO THE FILING DATE OF THE APPLICATION			
APPLICATION NUMBER	COUNTRY	DATE OF FILING (MAY, MONTH, YEAR)	PRIORITY CLAIMED
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

PROVISIONAL APPLICATION NUMBER	FILING DATE
60/248,447	November 14, 2000
60/382,341	May 28, 2002

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, inasmuch as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information known to me which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which becomes available between the filing date of the prior application and the national or PCT international filing date of this application:

NON-PROVISIONAL APPLICATION NO.	FILING DATE	STATUS		
		PATENTED	PENDING	ABANDONED
10/446,394	May 28, 2003		X	
10/497,661	May 13, 2003		X	
PCT/IL01/01060	November 12, 2001		X	

* For use only when the application is assigned to a company, partnership or other organization.





- 1 -

G '1 C/R '04

700705K R 7/1K MAN

71:61 5007:43R '57

WENTON & STRAWN DOCKET NO. 86189-498

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.				
2	FULL NAME OF INVENTOR	LAST NAME SHAHAR	FIRST NAME Abraham	MIDDLE NAME
0	RESIDENCE & CITIZENSHIP	CITY Rahovot	STATE OR FOREIGN COUNTRY Israel	COUNTRY OF CITIZENSHIP Israel
1	POST OFFICE ADDRESS	POSTAL CODE 76284	CITY Rahovot	STATE OR COUNTRY Israel
SIGNATURE OF INVENTOR 101 				DATE 15.9.2003
2	FULL NAME OF INVENTOR	LAST NAME NEVO	FIRST NAME Zvi	MIDDLE NAME
0	RESIDENCE & CITIZENSHIP	CITY Herzlia	STATE OR FOREIGN COUNTRY Israel	COUNTRY OF CITIZENSHIP Israel
2	POST OFFICE ADDRESS	POSTAL CODE 46425	CITY Herzlia	STATE OR COUNTRY Israel
SIGNATURE OF INVENTOR 202 				DATE 15.9.03
2	FULL NAME OF INVENTOR	LAST NAME ROCHKIND	FIRST NAME Shimon	MIDDLE NAME
0	RESIDENCE & CITIZENSHIP	CITY Ramat Aviv Givat	STATE OR FOREIGN COUNTRY Israel	COUNTRY OF CITIZENSHIP Israel
3	POST OFFICE ADDRESS	POSTAL CODE 49499	CITY Ramat Aviv Givat	STATE OR COUNTRY Israel
SIGNATURE OF INVENTOR 303 				DATE 15.9.03
2	FULL NAME OF INVENTOR	LAST NAME Shahar	FIRST NAME Abraham	MIDDLE NAME
0	RESIDENCE & CITIZENSHIP	CITY Ness-Ziona	STATE OR FOREIGN COUNTRY Israel	COUNTRY OF CITIZENSHIP ISRAEL
4	POST OFFICE ADDRESS	POSTAL CODE 74001	CITY Ness-Ziona	STATE OR COUNTRY Israel
SIGNATURE OF INVENTOR 304 				DATE 15.9.2003